Aptose Biosciences Inc (O:APTO)

Business Focus: Biotechnology & Medical Research

Mar 26, 2024 04:01 pm ET
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for...
Mar 18, 2024 04:30 pm ET
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year...
Jan 31, 2024 04:01 pm ET
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the...
Jan 26, 2024 08:31 am ET
Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose Biosciences?
NEW YORK, Jan. 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CIFR, SOUN, CLRB, BTDR, and APTO.
Jan 26, 2024 08:00 am ET
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the pricing of an...
Dec 09, 2023 06:30 pm ET
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that a growing body of...
Nov 30, 2023 04:59 pm ET
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of...
Nov 09, 2023 04:00 pm ET
Aptose Reports Results for the Third Quarter 2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for...
Nov 02, 2023 09:00 am ET
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that clinical data for...
Oct 30, 2023 09:15 am ET
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, released highlights from a clinical...
Oct 26, 2023 07:11 am ET
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended...
Oct 23, 2023 07:30 am ET
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Company...
Oct 16, 2023 07:30 am ET
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts...
Sep 18, 2023 07:45 am ET
Aptose to Present at the Cantor Global Healthcare Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose...
Sep 06, 2023 07:45 am ET
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced closing of a $3...
Aug 24, 2023 07:30 am ET
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose...
Aug 10, 2023 04:02 pm ET
Aptose Reports Results for the Second Quarter 2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for...
Jul 27, 2023 04:04 pm ET
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ended June...
Jun 26, 2023 04:05 pm ET
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it received a...
Jun 10, 2023 12:00 pm ET
Aptose Presents Highlights from Clinical Update
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a...
Jun 05, 2023 07:30 am ET
Aptose Biosciences Provides Update on Reverse Stock Split
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the Company...
May 31, 2023 07:30 am ET
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the company...
May 25, 2023 04:14 pm ET
Aptose Enters into $25 Million Committed Equity Facility
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered...
May 23, 2023 05:30 pm ET
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that, at the...
May 08, 2023 04:01 pm ET
Aptose Reports Results for the First Quarter 2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for...
May 04, 2023 07:01 am ET
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President...
Apr 24, 2023 07:01 am ET
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March...
Apr 10, 2023 04:01 pm ET
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G....
Mar 28, 2023 04:01 pm ET
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in...
Mar 23, 2023 04:44 pm ET
Aptose Reports Results for the Fourth Quarter and Full Year 2022
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...
Mar 10, 2023 06:44 pm ET
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to...
Mar 09, 2023 04:05 pm ET
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full...
Mar 02, 2023 07:30 am ET
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...
Jan 30, 2023 07:00 am ET
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor...
Dec 28, 2022 07:30 am ET
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...
Dec 12, 2022 06:15 am ET
Aptose Biosciences Establishes New At-The-Market Facility
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced it has entered into...
Dec 11, 2022 09:00 am ET
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today provided a clinical update of its lead oral myeloid kinome inhibitor, tuspetinib (formerly HM43239), as responses continue to emerge from a Phase 1/2 trial, and from its oral, dual...
Dec 07, 2022 04:05 pm ET
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company’s...
Nov 14, 2022 07:30 am ET
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous...
Nov 03, 2022 09:10 am ET
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tuspetinib (formerly HM43239),...
Nov 01, 2022 04:01 pm ET
Aptose Reports Results for the Third Quarter 2022
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...
Oct 18, 2022 04:01 pm ET
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September...
Sep 14, 2022 07:30 am ET
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose...
Sep 13, 2022 07:30 am ET
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of...
Sep 12, 2022 07:30 am ET
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the G3 formulation...
Aug 30, 2022 07:30 am ET
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose...
Aug 02, 2022 04:01 pm ET
Aptose Reports Results for the Second Quarter 2022
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...
Jul 27, 2022 07:30 am ET
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G....
Jul 19, 2022 04:01 pm ET
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30,...
Jun 27, 2022 07:30 am ET
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of...
Jun 02, 2022 08:10 pm ET
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
In a release issued under the same headline earlier today by Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS), please note that in the section of updated clinical findings with HM43239, the fifth bullet point should read "Eight total responses,...
Jun 02, 2022 05:30 pm ET
Aptose Presents Highlights from Corporate Update and KOL Event
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a...
May 31, 2022 04:15 pm ET
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results...
May 25, 2022 08:30 am ET
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it will host a key opinion leader (KOL)...
May 12, 2022 10:00 am ET
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company...
May 09, 2022 04:01 pm ET
Aptose Reports Results for the First Quarter 2022
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...
May 04, 2022 07:30 am ET
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the U.S. Food...
May 03, 2022 07:30 am ET
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G....
May 02, 2022 04:10 pm ET
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today highlighted recent...
Apr 25, 2022 07:30 am ET
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31,...
Apr 07, 2022 07:00 am ET
Aptose Announces Executive Management Changes
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of...
Mar 31, 2022 07:30 am ET
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G....
Mar 22, 2022 04:01 pm ET
Aptose Reports Results for the Fourth Quarter and Full Year 2021
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...
Mar 08, 2022 07:30 am ET
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended...
Mar 01, 2022 07:30 am ET
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Dec 29, 2021 07:30 am ET
Aptose to Participate in Two Biotech Events in January 2022
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners...
Dec 20, 2021 07:30 am ET
Aptose Provides Update on APTO-253 Program
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253. The decision follows prioritization of the company’s other more advanced pipeline candidates, as well...
Dec 13, 2021 04:30 pm ET
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML). Data were...
Dec 02, 2021 08:31 am ET
Thinking about buying stock in RLX Technology, Remark Holdings, Aptose Biosciences, Outlook Therapeutics, or Alpha Pro Tech?
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RLX, MARK, APTO, OTLK, and APT.
Nov 29, 2021 07:30 am ET
Aptose to Hold Corporate Update Monday, December 13th
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a...
Nov 22, 2021 04:02 pm ET
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the...
Nov 11, 2021 04:01 pm ET
Aptose Reports Results for the Third Quarter 2021
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months...
Nov 04, 2021 09:00 am ET
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for HM43239, a myeloid kinome...
Nov 04, 2021 06:00 am ET
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), announced today that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly...
Oct 26, 2021 07:30 am ET
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and...
Oct 25, 2021 08:00 am ET
Aptose Expands Senior Leadership Team
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the appointment of two key members to its management team to...
Aug 30, 2021 07:30 am ET
Aptose to Present at September Investor Conferences
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the...
Aug 03, 2021 04:01 pm ET
Aptose Reports Results for the Second Quarter 2021
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months...
Jul 20, 2021 04:01 pm ET
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide...
Jun 11, 2021 07:55 am ET
Aptose Presents Highlights from EHA During Corporate Update Event
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update...
Jun 01, 2021 04:30 pm ET
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the...
May 27, 2021 07:30 am ET
Aptose to Hold Corporate Update Friday, June 11th
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a...
May 12, 2021 07:30 am ET
Aptose to Present at Upcoming Investor Conferences
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming...
May 04, 2021 04:01 pm ET
Aptose Reports Results for the First Quarter 2021
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months...
Apr 26, 2021 04:02 pm ET
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021  
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and...
Apr 08, 2021 07:30 am ET
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Mar 23, 2021 04:01 pm ET
Aptose Reports Results for the Fourth Quarter and Full Year 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three...
Mar 16, 2021 07:30 am ET
Aptose Expands Senior Leadership Team
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the appointment of two key members to its management team to...
Mar 02, 2021 04:02 pm ET
Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31,...
Dec 06, 2020 05:30 pm ET
Aptose Presents Highlights from ASH and Corporate Update Event
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology (ASH) Annual Meeting. The...
Dec 01, 2020 07:30 am ET
Aptose to Hold Corporate Update Sunday, December 6th
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a...
Nov 10, 2020 04:01 pm ET
Aptose Reports Results for the Third Quarter 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and a corporate update...
Nov 04, 2020 10:17 am ET
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that early clinical data, along with certain...
Oct 27, 2020 04:01 pm ET
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on...
Oct 19, 2020 07:00 am ET
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced dosing of the first patient with acute...
Sep 15, 2020 07:30 am ET
Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Sep 09, 2020 07:30 am ET
Aptose to Present at September Investor Conferences
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Aug 06, 2020 07:30 am ET
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Aug 04, 2020 04:01 pm ET
Aptose Reports Results for the Second Quarter 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update...
Jul 21, 2020 04:01 pm ET
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on...
Jul 15, 2020 10:49 pm ET
Aptose Announces Pricing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,500,000 common shares (the “Offering”) at a public offering price of US$5.25...
Jul 15, 2020 04:01 pm ET
Aptose Announces Proposed Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the underwriters a 30-day...
Jun 29, 2020 09:31 am ET
Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp?
NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL.
Jun 29, 2020 07:01 am ET
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S. Food and Drug Administration (FDA) completed its...
Jun 12, 2020 07:00 am ET
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806,...
Jun 02, 2020 05:49 pm ET
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the...
May 14, 2020 09:00 am ET
Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806,...
May 07, 2020 07:30 am ET
Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor...
May 05, 2020 04:17 pm ET
Aptose Biosciences Establishes New At-The-Market Facility
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced that it has entered into an equity...
May 05, 2020 04:00 pm ET
Aptose Reports Results for the First Quarter 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update...
Apr 27, 2020 09:00 am ET
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today presented the early clinical data on CG-806, the company’s oral,...
Apr 24, 2020 07:30 am ET
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement...
Apr 21, 2020 07:30 am ET
Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March 31, 2020, on...
Mar 10, 2020 04:02 pm ET
Aptose Reports Results for the Fourth Quarter and Full Year 2019
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three...
Feb 25, 2020 07:31 am ET
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter and year ended December 31,...
Jan 29, 2020 07:30 am ET
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will host a key opinion leader (KOL) event on...
Jan 07, 2020 07:30 am ET
Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Dec 19, 2019 04:02 pm ET
Aptose Announces Closing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00...
Dec 17, 2019 08:00 am ET
Aptose Announces Pricing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross...
Dec 16, 2019 04:19 pm ET
Aptose Announces Proposed Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a...
Dec 09, 2019 11:00 am ET
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation of preclinical data for its...
Dec 07, 2019 11:00 am ET
Aptose Presents Highlights From Corporate Event At ASH
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the...
Dec 04, 2019 07:30 am ET
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of...
Dec 02, 2019 07:30 am ET
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 31st...
Nov 07, 2019 07:30 am ET
Aptose to Present at BIO-Europe Conference
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 25th...
Nov 06, 2019 09:54 am ET
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company will be hosting an Event at the 61st...
Nov 05, 2019 04:02 pm ET
Aptose Reports Results for the Third Quarter Ended September 30, 2019
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
Oct 22, 2019 07:00 am ET
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
Oct 10, 2019 07:30 am ET
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D.,...
Sep 16, 2019 07:30 am ET
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman,...
Aug 06, 2019 04:00 pm ET
Aptose Reports Results for the Second Quarter Ended June 30, 2019
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
Jul 30, 2019 07:30 am ET
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Jul 23, 2019 07:30 am ET
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
Jul 16, 2019 07:05 am ET
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing of CG-806, the company’s highly potent,...
Jun 14, 2019 07:00 am ET
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for...
Jun 04, 2019 04:02 pm ET
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the voting results from the...
Jun 03, 2019 09:00 am ET
Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Jotin Marango, M.D., Ph.D., to the position...
Jun 03, 2019 08:38 am ET
Aptose Announces Closing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to the public of $1.85 per share, including...
May 31, 2019 08:00 am ET
Aptose to Present at the Jefferies 2019 Healthcare Conference
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
May 30, 2019 09:01 am ET
Aptose Announces Pricing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,000,000 common shares at a price of $1.85 per share (the “Offering”) before...
May 29, 2019 04:22 pm ET
Aptose Announces Proposed Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common Shares (the “Offering”). In addition, Aptose intends to grant the underwriters a...
May 24, 2019 05:43 pm ET
Aptose Biosciences Establishes New At-The-Market Facility
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that it has entered into an...
May 16, 2019 10:02 am ET
Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for...
May 13, 2019 08:15 am ET
Aptose to Present at May Investor Conferences
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
May 10, 2019 07:24 pm ET
Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced, further to its approval by the...
May 07, 2019 04:01 pm ET
Aptose Reports Results for the First Quarter Ended March 31, 2019
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
Apr 24, 2019 07:30 am ET
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
Apr 23, 2019 07:30 am ET
Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
Apr 19, 2019 07:50 am ET
Report: Exploring Fundamental Drivers Behind Murphy Oil, Clean Harbors, OncoMed Pharmaceuticals, RiceBran Technologies, Zedge, and Aptose Biosciences — New Horizons, Emerging Trends, and Upcoming Deve
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Murphy Oil Corporation (NYSE:MUR), Clean Harbors, Inc. (NYSE:CLH),...
Apr 02, 2019 07:00 am ET
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Apr 01, 2019 01:00 pm ET
Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for...
Mar 25, 2019 07:02 am ET
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S. Food and Drug...
Mar 12, 2019 04:02 pm ET
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the year and...
Mar 07, 2019 07:00 am ET
Aptose to Participate in Upcoming Investor Conferences in March 2019
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Mar 04, 2019 07:00 am ET
Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the Australian Patent Office (“APO”) has issued Australian Patent No. 2013371146 for CG-806, a first-in-class, highly potent oral small molecule...
Feb 28, 2019 07:00 am ET
Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that preclinical data for CG-806,...
Feb 26, 2019 07:30 am ET
Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...
Feb 25, 2019 07:00 am ET
Aptose Biosciences Submits IND Application for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New Drug (IND) application for CG-806 to the U.S. Food and Drug Administration (FDA) requesting approval to...
Feb 19, 2019 07:30 am ET
Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Jan 02, 2019 07:25 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within The TJX Companies, Nasdaq, Werner Enterprises, Global Ship Lease, Domo, and Aptose Biosciences — New Research Emphasizes Economic Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The TJX Companies, Inc. (NYSE:TJX), Nasdaq, Inc. (NASDAQ:NDAQ), Werner...
Jan 02, 2019 07:05 am ET
Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Dec 12, 2018 10:00 am ET
Aptose Presents Highlights From CG-806 KOL Event
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL) breakfast featuring a presentation by Brian Druker, M.D., Professor of Medicine at the School of Medicine at Oregon Health & Science University...
Dec 03, 2018 07:10 am ET
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data demonstrating that CG-806, a first-in-class pan-FLT3/pan-BTK inhibitor, exhibits broad ex vivo...
Dec 03, 2018 07:05 am ET
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The University of Texas MD Anderson Cancer Center exploring the mechanism by which CG-806, a highly potent pan-FLT3/pan-BTK...
Nov 26, 2018 07:05 am ET
Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing has commenced in the first patient in its Phase 1b...
Nov 20, 2018 07:05 am ET
Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D.,...
Nov 14, 2018 08:40 am ET
New Research: Key Drivers of Growth for WellCare Health Plans, Streamline Health Solutions, Aptose Biosciences, Houston Wire & Cable, RTI Surgical, and Atlantica Yield — Factors of Influence, Major In
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of WellCare Health Plans, Inc. (NYSE:WCG), Streamline Health Solutions,...
Nov 06, 2018 04:05 pm ET
Aptose Reports Results for the Third Quarter Ended September 30, 2018
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
Nov 01, 2018 09:26 am ET
Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that preclinical data for its...
Oct 23, 2018 07:05 am ET
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2018 on...
Sep 27, 2018 07:05 am ET
Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940014B1 for CG-806, a first-in-class, highly potent oral small molecule being...
Sep 25, 2018 07:05 am ET
Aptose to Present at Upcoming Investor Conferences in October 2018
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Aug 29, 2018 07:05 am ET
Aptose to Present at Upcoming Investor Conferences in September 2018
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Aug 15, 2018 07:05 am ET
Aptose Announces Appointment of Carol Ashe to Board of Directors
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Ms. Carol Ashe to the Board of Directors...
Aug 07, 2018 04:18 pm ET
Aptose Reports Results for the Second Quarter Ended June 30, 2018
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
Aug 02, 2018 07:05 am ET
Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Jul 31, 2018 08:00 am ET
Aptose to Present at the 2018 Global Congress on Oncology and Cancer
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...
Jul 24, 2018 07:05 am ET
Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2018 on...
Jul 10, 2018 07:00 am ET
Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), today announced that the Japan Patent Office has issued Japanese Patent No. 6325573 for CG-806. The granted patent claims various compounds, including the CG-806 compound,...
Jul 09, 2018 07:00 am ET
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming...
Jun 29, 2018 07:00 am ET
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers....
Jun 15, 2018 08:00 am ET
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG-806, a highly potent pan-FLT3/pan-BTK inhibitor, exhibits a distinct mechanism of action and greater potency on...
Jun 14, 2018 07:05 am ET
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that they have entered into a license agreement with CrystalGenomics, Inc. (KOSDAQ:083790) for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau)....
Jun 05, 2018 04:05 pm ET
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the voting results from the Company’s...
Jun 04, 2018 07:04 am ET
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the publication of preclinical data elucidating the mechanism of action of APTO-253, the company’s clinical stage anticancer product candidate. The data are published in two separate...
May 31, 2018 07:04 am ET
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that it has entered into a Common...
May 17, 2018 11:43 am ET
Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for CG’806,...
May 10, 2018 04:00 pm ET
Aptose Reports Results for the First Quarter Ended March 31, 2018
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three...
May 07, 2018 07:00 am ET
Aptose Exercises Early Option for CG-806 License From CrystalGenomics
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced that Aptose exercised its option under the 2016 Option Agreement to exclusively license CG-806, a first-in-class, non-covalent pan-inhibitor...
May 01, 2018 07:30 am ET
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018
SAN DIEGO and TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs...
Apr 25, 2018 07:00 am ET
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the...
Apr 24, 2018 07:00 am ET
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018
SAN DIEGO and TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....
Apr 17, 2018 02:00 pm ET
Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting
Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253
Apr 16, 2018 07:30 am ET
Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting
CG’806 targets multiple pathways and kills cancer cells resistant to other FLT3 and BTK inhibitors
Apr 16, 2018 07:30 am ET
OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting
CG’806 Continues to Demonstrate Superior Activity to Other FLT3 and BTK Inhibitors Against Patient Samples
Apr 03, 2018 08:00 am ET
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
SAN DIEGO and TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....
Mar 28, 2018 08:00 am ET
Aptose Biosciences Establishes New At-the-Market Facility
SAN DIEGO and TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that it has...
Mar 27, 2018 04:15 pm ET
Mar 15, 2018 07:05 am ET
Aptose to Present New CG’806 and APTO-253 Data at the 2018 AACR Annual Meeting
SAN DIEGO and TORONTO, March 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that preclinical data for...
Mar 08, 2018 07:00 am ET
Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018
SAN DIEGO and TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.